Ultomiris (ravulizumab-cwvz) is a prescription drug that treats certain rare inflammatory conditions in some people. Learn about dosage, side effects, and more.

Now that Ultomiris has matched the indications of its predecessor Soliris, AstraZeneca is eyeing new avenues for the C5 drug to make its mark. Next up, the complement inhibitor—which AZ ...

AstraZeneca’s Ultomiris shows promise in rare post-transplant complication There are currently no approved treatment options for HSCT-TMA AstraZeneca (AZ) has announced promising results from a ...

AstraZeneca has been successful at rolling out its long-acting complement C5 inhibitor Ultomiris in the uses approved for its predecessor Soliris – until now, that is. The drugmaker confirmed ...

Alexion to present seven abstracts, including four oral presentations, from its leading rare neurology portfolio at EAN 2025: Cambridge, UK Monday, June 23, 2025, 13:00 Hrs [IST] ...

Ultomiris was compared to an external placebo arm from the pivotal Soliris PREVENT trial in NMOSD, showing a 99% reduction in relapses at that time point, with zero seen in the active treatment group.

Alexion, AstraZeneca Rare Disease, will present seven abstracts, including four oral presentations, from its leading rare neurology portfolio at the European Academy of Neurology (EAN) Annual Congress ...

Its rare diseases products include Soliris, Ultomiris, Strensiq and Kanuma. Its biopharmaceuticals products include Farxiga, Crestor, Breztri and others.

Initiative’s growth came almost entirely from 11 existing pharma clients, including AstraZeneca, Bristol Myers Squibb, Merck and Gilead. It added work from Alexion Pharmaceuticals for Ultomiris.

Biologics revolutionize generalized myasthenia gravis care with fast-acting, patient-friendly therapies and a robust global pipeline redefining outcomes. The gMG treatment era is shifting rapidly-from ...